These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 12220974)

  • 1. Hepatotoxicity following nevirapine-containing regimens in HIV-1-infected individuals.
    De Maat MM; Mathôt RA; Veldkamp AI; Huitma AD; Mulder JW; Meenhorst PL; Van Gorp EC; Carlier H; Beijnen JH
    Pharmacol Res; 2002 Sep; 46(3):295-300. PubMed ID: 12220974
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of severe hepatic events associated with nevirapine-containing regimens: CD4+ T-cell count and gender in hepatitis C seropositive and seronegative patients.
    Torti C; Costarelli S; De Silvestri A; Quiros-Roldan E; Lapadula G; Cologni G; Paraninfo G; Castelnuovo F; Puoti M; Carosi G;
    Drug Saf; 2007; 30(12):1161-9. PubMed ID: 18035868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy.
    Martínez E; Blanco JL; Arnaiz JA; Pérez-Cuevas JB; Mocroft A; Cruceta A; Marcos MA; Milinkovic A; García-Viejo MA; Mallolas J; Carné X; Phillips A; Gatell JM
    AIDS; 2001 Jul; 15(10):1261-8. PubMed ID: 11426070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections.
    Sulkowski MS; Thomas DL; Mehta SH; Chaisson RE; Moore RD
    Hepatology; 2002 Jan; 35(1):182-9. PubMed ID: 11786975
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiretroviral-associated toxicity among HIV-1-seropositive pregnant women in Mozambique receiving nevirapine-based regimens.
    Jamisse L; Balkus J; Hitti J; Gloyd S; Manuel R; Osman N; Djedje M; Farquhar C
    J Acquir Immune Defic Syndr; 2007 Apr; 44(4):371-6. PubMed ID: 17259905
    [TBL] [Abstract][Full Text] [Related]  

  • 6. No relationship between high nevirapine plasma concentration and hepatotoxicity in HIV-1-infected patients naive of antiretroviral treatment or switched from protease inhibitors.
    Dailly E; Billaud E; Reliquet V; Breurec S; Perré P; Léautez S; Jolliet P; Bourin M; Raffi F
    Eur J Clin Pharmacol; 2004 Jul; 60(5):343-8. PubMed ID: 15156302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence and risk factors of skin rashes and hepatotoxicity in HIV-infected patients receiving nevirapine-containing combination antiretroviral therapy in Taiwan.
    Tseng YT; Yang CJ; Chang SY; Lin SW; Tsai MS; Liu WC; Wu PY; Su YC; Luo YZ; Yang SP; Hung CC; Chang SC
    Int J Infect Dis; 2014 Dec; 29():12-7. PubMed ID: 25312984
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects.
    Sanne I; Mommeja-Marin H; Hinkle J; Bartlett JA; Lederman MM; Maartens G; Wakeford C; Shaw A; Quinn J; Gish RG; Rousseau F
    J Infect Dis; 2005 Mar; 191(6):825-9. PubMed ID: 15717255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HBV, HCV, and HBV/HCV co-infection among HIV-positive patients in Hunan province, China: Regimen selection, hepatotoxicity, and antiretroviral therapy outcome.
    Su S; Fairley CK; Sasadeusz J; He J; Wei X; Zeng H; Jing J; Mao L; Chen X; Zhang L
    J Med Virol; 2018 Mar; 90(3):518-525. PubMed ID: 29091279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence and risk factors for liver enzyme elevation during highly active antiretroviral therapy in HIV-HCV co-infected patients: results from the Italian EPOKA-MASTER Cohort.
    Torti C; Lapadula G; Casari S; Puoti M; Nelson M; Quiros-Roldan E; Bella D; Pastore G; Ladisa N; Minoli L; Sotgiu G; Mazzotta F; Lo Caputo S; Di Perri G; Filice G; Tinelli C; Carosi G;
    BMC Infect Dis; 2005 Jul; 5():58. PubMed ID: 16018804
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liver toxicity caused by nevirapine.
    González de Requena D; Núñez M; Jiménez-Nácher I; Soriano V
    AIDS; 2002 Jan; 16(2):290-1. PubMed ID: 11807315
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk and determinants of developing severe liver toxicity during therapy with nevirapine-and efavirenz-containing regimens in HIV-infected patients.
    Ena J; Amador C; Benito C; Fenoll V; Pasquau F
    Int J STD AIDS; 2003 Nov; 14(11):776-81. PubMed ID: 14624743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatotoxicity in patients prescribed efavirenz or nevirapine.
    Brück S; Witte S; Brust J; Schuster D; Mosthaf F; Procaccianti M; Rump JA; Klinker H; Petzold D; Hartmann M
    Eur J Med Res; 2008 Jul; 13(7):343-8. PubMed ID: 18700192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population pharmacokinetics of nevirapine in an unselected cohort of HIV-1-infected individuals.
    de Maat MM; Huitema AD; Mulder JW; Meenhorst PL; van Gorp EC; Beijnen JH
    Br J Clin Pharmacol; 2002 Oct; 54(4):378-85. PubMed ID: 12392585
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence and risk factors for nevirapine-associated rash.
    de Maat MM; ter Heine R; Mulder JW; Meenhorst PL; Mairuhu AT; van Gorp EC; Huitema AD; Beijnen JH
    Eur J Clin Pharmacol; 2003 Sep; 59(5-6):457-62. PubMed ID: 12920493
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of antiretroviral drugs on liver fibrosis in HIV-infected patients with chronic hepatitis C: harmful impact of nevirapine.
    Macías J; Castellano V; Merchante N; Palacios RB; Mira JA; Sáez C; García-García JA; Lozano F; Gómez-Mateos JM; Pineda JA
    AIDS; 2004 Mar; 18(5):767-74. PubMed ID: 15075511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection.
    den Brinker M; Wit FW; Wertheim-van Dillen PM; Jurriaans S; Weel J; van Leeuwen R; Pakker NG; Reiss P; Danner SA; Weverling GJ; Lange JM
    AIDS; 2000 Dec; 14(18):2895-902. PubMed ID: 11153671
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and tolerability of nevirapine-based antiretroviral therapy in HIV-infected patients receiving fluconazole for cryptococcal prophylaxis: a retrospective cohort study.
    Manosuthi W; Chumpathat N; Chaovavanich A; Sungkanuparph S
    BMC Infect Dis; 2005 Aug; 5():67. PubMed ID: 16120209
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection.
    Sulkowski MS; Thomas DL; Chaisson RE; Moore RD
    JAMA; 2000 Jan; 283(1):74-80. PubMed ID: 10632283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy.
    Wit FW; Weverling GJ; Weel J; Jurriaans S; Lange JM
    J Infect Dis; 2002 Jul; 186(1):23-31. PubMed ID: 12089658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.